PRESS RELEASE

DUOPHARMA BIOTECH SIGNS WITH THE GOVERNMENT OF MALAYSIA TO SUPPLY RUSSIA’S COVID-19 VACCINE TO MALAYSIA

Following the signing with the Government of Malaysia, Duopharma Biotech’s Group MD confirmed the Company’s readiness and alignment with Malaysia’s COVID-19 national immunisation programme.

KUALA LUMPUR, 1 JUNE 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) through its wholly-owned subsidiary Duopharma (M) Sendirian Berhad (“DMSB”) has with the recent signing with the Government of Malaysia (“Government”), represented by the Ministry of Health, concluded execution of separate definitive supply agreements with the Government and a subsidiary of the Russian Direct Investment Fund (“RDIF”) for the supply of 6.4 million doses of the Sputnik V vaccine.

This follows the announcement made on 26 January 2021 of the signing by DMSB of separate Term Sheets with the Government and RDIF. The supply of the vaccine is subject to the fulfilment of the remaining condition precedent under the supply agreements, namely the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

“Sputnik V”, which was developed by Russia's Gamaleya National Research Institute of Epidemiology and Microbiology (“Gamaleya”), has since been successfully registered in 68 countries across North and South America, the Middle East, Europe, Asia and Africa. Three of the countries that have registered 'Sputnik V' - Hungary, Slovakia and Argentina - are members of the European Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Based on peer reviewed results of the second interim analysis Phase III published by one of the world’s oldest and most respected medical journals, The Lancet, “Sputnik V’s” efficacy has been confirmed at 91.6%. Furthermore, it is one of only three vaccines in the world with an efficacy rating of over 90%, and no serious adverse events related to the vaccine were recorded.

According to RDIF, 20 million people have so far received the vaccine globally with emergency use authorisation (EUA) registered in 64 countries. In addition to providing full protection against severe cases of COVID-19, “Sputnik V” is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. The safety, efficacy and lack of
negative long-term effects of adenoviral vector-based vaccines have been proven by more than 250 clinical studies over two decades.

Duopharma Biotech Group Managing Director, Leonard Ariff Abdul Shatar confirmed the Company’s state of readiness and commented: "The COVID-19 pandemic has presented all Malaysians with extraordinary challenges, which we can only overcome through immediate collaboration on many fronts: Duopharma Biotech is fully committed and proud to be part of our Nation’s inoculation programme."

-END-

ABOUT DUOPHARMA BIOTECH BERHAD

Duopharma Biotech Berhad Group (“Duopharma Biotech” or “the Company”) began with the establishment of Duopharma (M) Sendirian Berhad in 1978. Duopharma Biotech was incorporated in the year 2000 and is today, one of Malaysia’s leading pharmaceutical companies listed on the Main Market of Bursa Malaysia Berhad.

Duopharma Biotech has core competencies in the pharmaceutical industry inclusive of Manufacturing, Research & Development and Commercialisation & Marketing of over 300 generic drugs - among others, Omesec and Prellica as well as its Consumer Healthcare (CHC) products such as CHAMPS®, FLAVETTES®, PROVITON® and Uphamol, which are well recognised and accepted by consumers in Malaysia, regionally and globally. The Company has also diversified into the biosimilars space with technology and commercialisation collaborations with credible and strong international partners.

The Company’s headquarters is located in Kuala Lumpur, Malaysia. Duopharma Biotech owns and operates three manufacturing plants that are based in Klang, Bangi and Glenmarie, Selangor. Duopharma Biotech also has subsidiary companies in the Philippines and Singapore. A subsidiary of Duopharma Biotech Berhad has a representative office in Jakarta, Indonesia.

Website: www.duopharmabiotech.com

For more information please contact:

Eric Pringle Associates Public Relations Sdn Bhd
(Official Public Relations Agency of Duopharma Biotech Berhad)
Name: Art Thamboo / Ida Fazila Ismail
Telephone: +603 - 2161 7144
Email: art_thamboo@epapr.com.my / ida@epapr.com.my

Corporate Communication Department of Duopharma Biotech Berhad
Name: Nor Soleha Ab Shukor / Delaila Abdullah
Telephone: +6019 289 1008 / +6012 296 9639
Email: soleha@duopharmabiotech.com / delaila@duopharmabiotech.com